mGx M&A? Mod­er­na ex­ecs are lever­ag­ing their Covid cash on gene edit­ing, gene ther­a­py deals

Mod­er­na’s lit­tle busi­ness deal with Au­to­lus ear­li­er this week looks like a predin­ner snack ahead of the main course to come.

Dur­ing his Q2 call with an­a­lysts on Thurs­day, Mod­er­na CEO Stéphane Ban­cel got more than a few eye­brows to raise with his com­ments on BD plans. Now that the com­pa­ny’s mar­ket cap has hit an Ever­est-high cruis­ing al­ti­tude above $165 bil­lion — lev­i­tat­ing up 78% in the past month — with a megablock­buster gin­ning mon­ey on hand, Ban­cel is pre­pared to put that cash and kind to use. And he made it clear that gene edit­ing/gene ther­a­pies are right at the heart of this new move.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE